Barclays Forecasts Strong Price Appreciation for Tenet Healthcare (NYSE:THC) Stock

Key Points

• Barclays raised its Tenet Healthcare price target to $297 from $271 and reiterated an Overweight rating, implying 2.54% upside from the prior close.
• Analyst sentiment is broadly positive: 20 analysts rate the stock Buy and three Hold, with a consensus “Moderate Buy” rating and an average target of $293.48.
• Tenet reported quarterly EPS of $6.64, beating estimates of $4.68, while revenue of $6.28 billion also topped expectations and increased 6.5% year over year.

Tenet Healthcare (NYSE:THC - Get Free Report) had its price target upped by equities researchers at Barclays from $271.00 to $297.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 2.54% from the company's previous close.

Several other equities analysts have also issued reports on THC. Stephens reissued an "overweight" rating and issued a $285.00 price target on shares of Tenet Healthcare in a report on Monday, July 27th. BMO Capital Markets initiated coverage on Tenet Healthcare in a report on Tuesday, September 22nd. They set a "market perform" rating and a $265.00 target price on the stock. Truist Financial reissued a "buy" rating and issued a $305.00 target price (up from $290.00) on shares of Tenet Healthcare in a research note on Tuesday. Deutsche Bank Aktiengesellschaft increased their price target on Tenet Healthcare from $260.00 to $320.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Finally, UBS Group lifted their price objective on Tenet Healthcare from $288.00 to $308.00 and gave the company a "buy" rating in a report on Monday, July 27th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Tenet Healthcare presently has a consensus rating of "Moderate Buy" and an average price target of $293.48.

Tenet Healthcare Stock Up 8.6%

Shares of THC stock traded up $22.94 during trading hours on Wednesday, reaching $289.63. The company had a trading volume of 1,112,848 shares, compared to its average volume of 1,120,621. The company has a market capitalization of $23.05 billion, a P/E ratio of 8.40, a price-to-earnings-growth ratio of 1.44 and a beta of 1.20. The stock's fifty day simple moving average is $264.37 and its 200 day simple moving average is $221.04. Tenet Healthcare has a twelve month low of $157.58 and a twelve month high of $292.50. The company has a debt-to-equity ratio of 1.76, a quick ratio of 1.52 and a current ratio of 1.58.

Tenet Healthcare (NYSE:THC - Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $6.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.68 by $1.96. Tenet Healthcare had a net margin of 13.09% and a return on equity of 28.22%. The firm had revenue of $6.28 billion during the quarter, compared to analyst estimates of $5.49 billion. During the same period in the previous year, the business posted $3.70 EPS. Tenet Healthcare's revenue was up 6.5% on a year-over-year basis. As a group, sell-side analysts expect that Tenet Healthcare will post 22.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Tenet Healthcare

In other Tenet Healthcare news, Director Tammy Romo sold 4,922 shares of Tenet Healthcare stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $264.15, for a total transaction of $1,300,146.30. Following the transaction, the director directly owned 30,784 shares of the company's stock, valued at $8,131,593.60. The trade was a 13.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lisa Foo sold 24,000 shares of the company's stock in a transaction on Monday, August 31st. The stock was sold at an average price of $266.32, for a total transaction of $6,391,680.00. Following the completion of the transaction, the executive vice president directly owned 8,053 shares in the company, valued at approximately $2,144,674.96. The trade was a 74.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 105,884 shares of company stock worth $28,740,455. 0.97% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of THC. Ashton Thomas Private Wealth LLC grew its holdings in Tenet Healthcare by 1.7% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,468 shares of the company's stock worth $631,000 after acquiring an additional 42 shares in the last quarter. PeakShares LLC raised its stake in shares of Tenet Healthcare by 3.3% in the 1st quarter. PeakShares LLC now owns 1,693 shares of the company's stock valued at $319,000 after purchasing an additional 54 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of Tenet Healthcare by 4.4% in the 3rd quarter. Parallel Advisors LLC now owns 1,282 shares of the company's stock valued at $328,000 after purchasing an additional 54 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Tenet Healthcare by 0.5% during the first quarter. Sanctuary Advisors LLC now owns 11,900 shares of the company's stock worth $2,246,000 after purchasing an additional 57 shares during the last quarter. Finally, Applied Finance Capital Management LLC grew its stake in Tenet Healthcare by 3.8% in the first quarter. Applied Finance Capital Management LLC now owns 1,644 shares of the company's stock worth $310,000 after purchasing an additional 60 shares in the last quarter. 95.44% of the stock is owned by hedge funds and other institutional investors.

Tenet Healthcare News Summary

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Truist Financial reaffirmed its Buy rating and raised its price target to $305 from $290, signaling continued confidence in Tenet’s prospects. Truist rating coverage
• Positive Sentiment: KeyCorp lifted its target to $300 from $270 and maintained an Overweight rating, adding to the recent run of bullish analyst revisions. KeyCorp target update
• Positive Sentiment: Leerink Partners raised its target to $342 from $309 and kept an Outperform rating. A separate report says Tenet raised its 2026 EBITDA outlook, a potentially important sign of improving earnings expectations. Tenet outlook report
• Positive Sentiment: Wells Fargo and Royal Bank of Canada are also reported to expect further share-price appreciation, adding to the broadly favorable analyst sentiment. Wells Fargo analyst report RBC analyst report
• Neutral Sentiment: Zacks noted increased investor interest in THC but did not provide a specific new catalyst or recommendation in the available article details. Zacks article

About Tenet Healthcare

Tenet Healthcare Corp. NYSE: THC is a diversified healthcare services company headquartered in Dallas, Texas. Through its hospital operations and outpatient platforms, the company provides a range of medical services to patients across the United States.

Tenet operates acute care and specialty hospitals, ambulatory surgery centers, imaging facilities and other outpatient care sites. Its United Surgical Partners International subsidiary is a major provider of ambulatory surgery services and partners with physicians and health systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.